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cohort study, with assessments of clinical outcomes every 6 months. Remission 
was defined as a mild or lower level on 8 key items of Positive And Negative 
Symptoms Scale (PANSS) - P1, P2, P3, N1, N4, N6, G5 and G9 - for at least 6 months. 
Symptomatic remission was described at each visit. Bivariate analyses were 
then conducted to compare groups in terms of symptoms severity, functioning, 
quality of life and economic burden. A repeated logistic model was finally used 
to identify risk factors associated with symptomatic remission. Results: The 
proportion of patients achieving symptomatic remission within 2 years was 36%. 
This outcome was found to be stable over time: 72% of patients achieving symp-
tomatic remission at any visit remained in remission at the next visit. Significant 
differences were found between groups in terms of severity (p < 0.0001), function-
ing (p < 0.0001), quality of life (p < 0.0001) and most of the resource use compo-
nents (p < 0.0001). Factors associated with remission included baseline depression 
level (p= 0.005), baseline severity of symptoms (p < 0.0001), baseline functioning 
(p < 0.0001), and compliance level (p < 0.0001). ConClusions: This research 
indicates that patients in symptomatic remission have better social function-
ing, better quality of life and lower resource use than other patients. Achieving 
symptomatic remission should be an important treatment goal in the treatment 
of schizophrenia.
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objeCtives: To assess the implications of conducting budget impact analyses 
from different perspectives when evaluating interventions used in remote/rural 
settings. In the case study, fomepizole vs. ethanol for methanol/ethylene glycol 
poisoning was assessed from perspectives of remote nursing stations and the 
health care system in Canada. Methods: Literature searches were undertaken 
to obtain cost and health care resource use information. Experts from Health 
Canada and the Alberta Poison and Drug Information Service were consulted to 
provide additional information and assist with interpretation and applicability of 
data. Results: From the perspective of the remote nursing station, fomepizole 
appears to be a more costly treatment than ethanol. However, this perspective 
only takes into account drug costs, nursing costs and transportation costs. Remote 
nursing stations cannot effectively monitor ethanol levels to ensure correct dosing 
without access to labs – fomepizole does not require dose monitoring; potentially 
impacting patient’s health. Where transfer to a tertiary care facility is delayed, 
continued treatment without lab monitoring may increase the likelihood of com-
plications from ethanol treatment, or methanol or ethylene glycol poisoning, lead-
ing to downstream health care resource use at tertiary care facilities (need for 
ICU, increased LOS), as well as impacting patient quality of life. ConClusions: 
Fomepizole is a costly treatment that reduces the burden on staff and may lead 
to improved outcomes for patients in the tertiary care setting. However, given 
that rural/remote nursing stations have to manage their own budgets, fomepizole 
may not be considered cost-effective compared to other treatment options when 
only considering the short time frame the patient is in their care (until transfer to 
tertiary care facility). Based on a broader perspective (health care payer or patient), 
implications beyond the budget may be relevant and as such, an economic evalua-
tion of fomepizole from a broader perspective would provide valuable information 
to the Canadian health care system.
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objeCtives: Buprenorphine/naloxone (BUP/NAL) for the treatment of opioid 
dependence combination is available in film (since September 2010) and tablet 
formulation. Earlier studies showed that treatment with BUP/NAL film formu-
lation leads to an improved treatment persistence and lower health care costs 
compared to BUP/NAL tablet formulation. A budget impact analysis was built to 
assess the health care expenditures related to new patients entering treatment in 
scenarios characterized by different market shares of the two BUP/NAL formula-
tions. Methods: A Markov model was structured tracking a cohort of patients 
initiating opioid dependence treatment with BUP/NAL film or BUP/NAL tablet 
formulation through successive phases of treatment: initiation, maintenance, dis-
continuation, off treatment and reinitiation. Transition probabilities and resource 
utilization were estimated from a Marketscan Multi-State Medicaid database. The 
total health care expenditure over five years was predicted for 65.6 million mem-
bers for the following scenarios: 1) 100% market share BUP/NAL film formulation, 
2) 100% market share BUP/NAL tablet formulation broken between all BUP/NAL 
tablet formulations currently available in the market. Results: In the first year, 
for Scenario 1 (100% on BUP/NAL Film) costs of medication acquisition were found 
to be %6.1 (-US$18.1 million) lower. Costs of outpatient care were 31.65% (US$110.6 
million) higher. Nevertheless, this difference was outweighed by lower costs of 
inpatient care (-36.09%) (-US$129.9 million), and emergency room (-7.96%) (-US$3.3 
million). Scenario 1 total health care costs were 4.2% and 9.4% lower in the first 
year and cumulatively over five years, respectively. ConClusions: Treatment 
with buprenorphine/naloxone film results in less health care resource utilization 
and lower total cost burden for Medicaid plans when compared to treatment with 
buprenorphine/naloxone tablet
of 26.95%. The most frequently prescribed drugs were oxybutynin (4.54%), solif-
enacin (4.48%), paroxetine (2.81%), tolterodine (2.47%) and promethazine (2.41%). 
Multivariable analysis revealed that fair/poor general health status (Odds Ratio, OR: 
5.09; 95% CI: 1.36-19.08), anxiety (OR: 3.02; 95% CI: 1.21-7.54) and mood disorder (OR: 
4.15; 95% CI: 1.87-9.22) increased the likelihood of receiving inappropriate anticho-
linergic medications, whereas age between 75 to 84 years (OR: 0.35; 95% CI: 0.15-0.81) 
decreased the likelihood of receiving inappropriate anticholinergic medications in 
elderly dementia patients. ConClusions: The study found that approximately one 
in four elderly patients with dementia used inappropriate anticholinergic medica-
tions. Given the significant cognitive effects of anticholinergic medications, there 
is an urgent need to monitor and optimize the use of anticholinergic medications 
in this vulnerable elderly population.
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objeCtives: To determine the pattern and predictors of ambulatory care visits 
for Substance Use Disorder (SUD) in adolescents and young adults. Methods: A 
retrospective cross-sectional study was conducted using the 2008-2010 National 
Ambulatory Medical Care Survey (NAMCS) data. Annual visits for SUD were esti-
mated using the ICD-9CM codes 303-305; descriptive statistics were performed on 
the weighted sample. Logistic regression was used to determine the predictors of 
SUD visits identified based on previous literature. Adolescents and young adults 
were defined as individuals 12-25 years of age. Results: An estimated 23.45 mil-
lion patient visits were attributable to SUD during 2008-2010. About 15.47% of these 
visits were by adolescents and young adults. Majority of these visits were by male 
(65.21%), white (89.33%), and had comorbid anxiety (23.43%), or bipolar disorder 
(29.78%). The probability of SUD related visit decreased by 5.3% [OR= 0.947, CI-0.939-
0.955] with each year increase in age. Males had twice the odds of SUD visit than 
females [OR= 2.193, CI-1.285-3.742]. No racial differences were found, although lit-
erature suggests racial variation in SUD. Likelihood of SUD visit was 72% lower 
[OR= 0.281, CI-0.129-0.615] in the West than in the Midwest. Literature suggests 
strong association between SUD and psychiatric comorbidities. The present study 
specifically found that comorbid anxiety or bipolar disorder increased the odds of 
SUD visits by 5.2 [OR= 5.220, CI-2.616-10.414] and 16.6 [OR= 16.625, CI-5.871-47.076] 
times respectively. Significant associations were observed between SUD visits and 
psychiatric co-medications. Patients receiving prescription for Alpha-2 agonists and 
mood-stabilizers had 10 [OR= 10.122, CI-1.618-63.323] and 2.4 [OR= 2.420, CI-1.085-
5.400] times higher odds of SUD visits respectively while receiving anxiolytics had 
an opposite effect [OR= 0.454, CI-0.208-0.989]. ConClusions: The findings of the 
study are in congruence with previous literature using adult samples. Study suggests 
early onset of SUD in children and adolescents with higher visit rates in patients 
with mood or anxiety disorders.
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objeCtives: Depressive symptoms are frequent clinical features in patients with 
schizophrenia. They contribute substantially to the burden of disease, and are 
associated with exacerbations of deficits in psychosocial functioning. The objec-
tive of this study was to describe prevalence and key risk factors associated with 
depressive symptoms, using data from a longitudinal cohort study. Methods: 
We used data from EuroSC, a multicenter 2-year cohort study conducted in France, 
England and Germany. The Calgary Depression Scale for Schizophrenia (CDSS), 
developed to assess the level of depressive symptoms in schizophrenia, was com-
pleted every 6 months, as well as other clinical outcomes (severity of symptoms, 
functioning, etc.) and quality of life. First, prevalence of depressive symptoms was 
described using several CDSS cut-offs. Correlations with other negative symptoms 
measures were also described. Then bivariate analyses were conducted to describe 
clinical outcomes and quality of life among patients with and without depressive 
symptoms. Finally, a repeated logistic model was implemented to identify key 
factors associated with depressive symptoms. Results: Our sample consisted in 
1208 patients with schizophrenia. The mean CDSS score at baseline was 0.93 (1.22). 
Prevalence of depressive symptoms ranged from 5% to 27.6% depending on CDSS 
cut-off used. Correlations with negative symptoms measures were all significant. 
Bivariate analyses suggested a higher clinical burden and a decreased quality of 
life for depressive patients. The multivariate model identified functioning, men-
tal composite score of SF36 and non-compliance level as key factors associated 
with depressive symptoms. ConClusions: This study shows that depressive 
symptoms associated with the antipsychotics have a significant impact on clini-
cal outcomes and quality of life, independently of the CDSS cut-off used. Key 
factors associated with depressive symptoms are functioning, quality of life and 
non-compliance.
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objeCtives: The typical course of schizophrenia starts with a premorbid phase, 
followed by a phase of symptomatic but unrecognised/treated disease, and 
acute exacerbations with more or less partial remission phases in between. The 
objective of this study is to describe patients with symptomatic remission in an 
observational longitudinal study of patients with schizophrenia, and to identify 
potential risk factors. Methods: We used data from EuroSC, a European 2-year 
